Introduction {#section5-1753466619888124}
============

Noninvasive ventilation (NIV) has been used increasingly in recent years.^[@bibr1-1753466619888124]^ It decreases the work of breathing in patients with hypoxemic respiratory failure, and avoids the need for endotracheal intubation in responders.^[@bibr2-1753466619888124],[@bibr3-1753466619888124]^ However, the NIV failure rate is high (31--54%) in patients with hypoxemic respiratory failure.^[@bibr4-1753466619888124][@bibr5-1753466619888124][@bibr6-1753466619888124]--[@bibr7-1753466619888124]^ Patients who experience NIV failure are more likely to die in hospital.^[@bibr8-1753466619888124][@bibr9-1753466619888124]--[@bibr10-1753466619888124]^ A possible reason is delayed intubation-associated complications.^[@bibr11-1753466619888124],[@bibr12-1753466619888124]^ Therefore, identifying patients who respond badly to NIV has potential value to reduce delayed intubation.

Sepsis syndrome is a common reason for morbidity and mortality in intensive care units (ICUs). The incidence of severe sepsis and septic shock is 11.8--12.6 patients per 100 ICU admissions.^[@bibr13-1753466619888124],[@bibr14-1753466619888124]^ If all patients with sepsis syndrome were included in the calculation, the incidence would be higher. Previous studies have reported that sepsis was associated with NIV failure.^[@bibr4-1753466619888124],[@bibr15-1753466619888124]^ However, they failed to describe the level of severity, efficacy and outcomes in septic patients who received NIV.

The aim of this study was to identify the association between sepsis and NIV failure in patients with hypoxemic respiratory failure. In addition, we further explored the outcomes between patients whose sepsis was induced by pulmonary and nonpulmonary infection.

Methods {#section6-1753466619888124}
=======

From September 2017 to July 2018, we performed a prospective multi-center observational study in 16 Chinese ICUs. Patients admitted to ICU for NIV due to hypoxemic respiratory failure were candidates. We enrolled patients as follows: respiratory rate more than 25 breaths/min, or clinical presentation of respiratory distress at rest (such as active contraction of the accessory inspiratory muscles or paradoxical abdominal motion), PaO~2~ of \<60 mmHg at room air or PaO~2~/ FiO~2~ \<300 with supplemental oxygen. However, we excluded patients as follows: pneumothorax, age less than 18 years, PaCO~2~ more than 50 mmHg, receipt of intubation for invasive mechanical ventilation preceding 48 h of NIV, and reaching the criteria of intubation but refuse to intubate before NIV. In addition, patients with cardiogenic pulmonary edema were also excluded. The Ethics Committee and Institutional Review Board (the First Affiliated Hospital of Chongqing Medical University) approved the study protocol (No. 2016150). Written informed consent was obtained from patients or their family members.

NIV was managed by attending physicians, respiratory therapists, and nurses. The attending physicians managed the whole use of NIV, including initiation and termination of NIV. The respiratory therapists and nurses assisted with managing the NIV, including interface selection, parameter setting, humidification management, and variable recording. All participating centers have a training protocol on how to use NIV, and all participants received strictly training before use of NIV. Selection of the oronasal mask was based on the patient's facial type. The straps of the mask were kept as tight as possible while remaining comfortable for the patient. If the oronasal mask was not tolerated, a nasal mask, full-face mask, or other interface can be selected. In patients with labored breathing, the bilevel positive pressure ventilation mode was used. In patients with cardiogenic pulmonary edema or pulmonary atelectasis, continuous positive airway pressure (CPAP) can be selected. The parameters were recommended to be gradually increased based on the patient tolerance. Positive-end expiratory pressure was maintained at 6--10 cm H~2~O. Inspiratory pressure was initially set at 8 cm H~2~O, and then increased in increments of 2 cm H~2~O to achieve the best control of dyspnea and tolerance of the patient. When the respiratory failure was reversed, liberation from NIV was considered. The reversal of respiratory failure was referenced as follows: the PaO~2~/FiO~2~ \>300, respiratory rate \<25 cycles/min, and no clinical symptoms indicating respiratory distress. The parameters were gradually decreased and the ventilator used intermittently until the patient was totally liberated from the ventilator. However, if respiratory failure progressively deteriorated and reached the criteria of intubation, intubation for invasive mechanical ventilation was recommended.

The criteria for intubation were as follows. Major criteria: respiratory or cardiac arrest, loss of consciousness (such as a sudden change from being awake to unconscious), development of conditions necessitating intubation to protect the airway (coma or seizure disorders) or to manage copious tracheal secretions, heart rate \<50 beats/min with loss of alertness, hemodynamic instability (mean arterial blood pressure \<65 mmHg) without response to fluids and vasoactive agents. Minor criteria: failure to maintain a PaO~2~/FiO~2~ more than 150, respiratory rate more than 35 breaths/min, acidosis with pH less than 7.35, inability to correct dyspnea, lacking improvement signs of respiratory muscle fatigue. Intubation was recommended if the patient reached one major criterion or more than two minor criteria. However, this was based on the attending physicians' discretion. NIV failure was defined as a requirement for intubation.

Sepsis and septic shock were diagnosed according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).^[@bibr16-1753466619888124]^ Immunosuppression was considered if one of the following was present: solid tumor with white blood cell counts (WBC) \<1 × 10^9^/l, hematological malignancy (such as myeloma, lymphoma, leukemia, etc.), administration of steroids at a dose greater than 0.3 mg/kg per day of prednisolone for more than 1 month, an immunosuppresive drug taken for more than 1 month, HIV infection, and solid organ transplant.^[@bibr17-1753466619888124][@bibr18-1753466619888124]--[@bibr19-1753466619888124]^ Patients with chronic obstructive pulmonary disease, chronic bronchitis, sequelae of pulmonary tuberculosis, bronchiectasis, obesity-hypoventilation syndrome or chest-wall deformity were diagnosed as chronic respiratory disease.^[@bibr20-1753466619888124]^ Patients with chronic heart failure, coronary artery disease, hypertensive or valvular heart diseases, and dilated myocardial disease were diagnosed as chronic heart disease.^[@bibr20-1753466619888124]^

Statistical analysis {#section7-1753466619888124}
--------------------

Normally distributed continuous variables were reported as mean value and standard deviation. Abnormally distributed continuous variables were reported as median value and interquartile range. The difference in two groups was analyzed by unpaired Student's *t* test or Mann--Whitney *U* test when appropriate; the difference in three groups was analyzed by one-way ANOVA or Kruskal-Wallis H test when appropriate. Categorical variables were reported as number and percentage, and difference between groups were analyzed by Chi-squared or Fisher's exact test. Variables with a *p* value less than 0.2 in the univariate analysis and other clinical meaningful variables were entered in a stepwise multivariate logistic regression analysis to identify independent risk factors associated with NIV failure. A *p* value less than 0.05 was considered statistically significant.

Results {#section8-1753466619888124}
=======

From September 2017 to July 2018, a total of 519 patients were enrolled. Sepsis developed in 365 patients (70%) and septic shock developed in 79 patients (15%). However, 75 patients (14%) had no sepsis or septic shock. The baseline data are summarized in [Table 1](#table1-1753466619888124){ref-type="table"}. The majority of sepsis syndrome was resulted from pulmonary source (78% in sepsis and 42% in septic shock, respectively). Univariate analysis revealed that sepsis and septic shock were highly associated with NIV failure \[odds ratio (OR) = 2.10, 95% confidence interval (CI): 1.17--3.75 and OR = 5.28, 95% CI: 2.61--10.69, respectively\] ([Table 2](#table2-1753466619888124){ref-type="table"}). Multivariate analysis also showed that sepsis and septic shock were independently associated with NIV failure (OR = 1.95, 95% CI: 1.06--3.61 and OR = 2.47, 95% CI: 1.12--5.45, respectively).

###### 

Baseline data.

![](10.1177_1753466619888124-table1)

                                            No sepsis (*n* = 75)   Sepsis (*n* = 365)   Septic shock (*n* = 79)   *p* ^[a](#table-fn2-1753466619888124){ref-type="table-fn"}^
  ----------------------------------------- ---------------------- -------------------- ------------------------- -------------------------------------------------------------
  Age, years                                56 ± 19                62 ± 18              60 ± 19                   0.03
  Male (%)                                  47 (63%)               246 (67%)            54 (68%)                  0.70
  APACHE II score                           13 ± 6                 15 ± 5               18 ± 5                    \<0.01
  SOFA score                                4.7 ± 2.2              4.9 ± 2.2            8.6 ± 3.2                 \<0.01
  Presence of immunosuppression             5 (7%)                 49 (13%)             8 (10%)                   0.22
  Site of infection                                                                                               
   Respiratory                              2 (2%)                 286 (78%)            33 (42%)                  
   Abdominal                                --                     41 (11%)             23 (29%)                  
   Urinary                                  --                     17 (5%)              16 (20%)                  
   Others                                   --                     21 (6%)              7 (9%)                    
  Comorbidity                                                                                                     
   Hypertension                             26 (35%)               145 (40%)            23 (29%)                  0.18
   Diabetes mellitus                        12 (16%)               86 (24%)             17 (22%)                  0.35
   Solid tumor                              18 (24%)               47 (13%)             13 (17%)                  0.05
   Chronic heart disease                    12 (16%)               71 (20%)             16 (20%)                  0.75
   Chronic respiratory disease              13 (17%)               56 (15%)             8 (10%)                   0.40
  Reasons for NIV                                                                                                 
   Pneumonia                                2 (3%)                 242 (66%)            34 (43%)                  \<0.01
   Pancreatitis                             18 (24%)               26 (7%)              4 (5%)                    \<0.01
   Postoperative respiratory failure        9 (12%)                35 (10%)             10 (13%)                  0.64
   Trauma                                   8 (11%)                14 (4%)              2 (3%)                    0.02
   Pulmonary embolism                       6 (8%)                 6 (2%)               0 (0%)                    \<0.01
   Pulmonary cancer                         5 (7%)                 2 (0.5%)             1 (1%)                    \<0.01
   Asthma                                   4 (5%)                 0 (0%)               0 (0%)                    \<0.01
   Poison                                   2 (3%)                 1 (0.3%)             0 (0%)                    0.03
   Ketoacidosis                             0 (0%)                 2 (0.5%)             1 (1%)                    0.58
   Cholangitis/cholecystitis                0 (0%)                 9 (3%)               6 (8%)                    0.01
   Interstitial lung disease                5 (7%)                 2 (0.5%)             0 (0%)                    \<0.01
   Others                                   16 (21%)               26 (7%)              21 (27%)                  \<0.01
  Laboratory tests                                                                                                
   White blood cell counts, ×10^9^/l        12 ± 6                 12 ± 8               14 ± 9                    0.22
   Platelet counts, ×10^9^/l                181 ± 106              196 ± 114            171 ± 126                 0.16
   Hemoglobin, mg/dl                        10.9 ± 2.9             11.0 ± 2.8           10.1 ± 3.0                0.07
   Albumin, g/l                             31 ± 6                 30 ± 6               29 ± 7                    0.21
   Potassium, mmol/l                        4.0 ± 0.7              4.0 ± 0.7            4.2 ± 0.9                 0.11
   Sodium, mmol/l                           138 ± 7                138 ± 6              139 ± 9                   0.10
   Chlorine, mmol/l                         104 ± 7                103 ± 7              105 ± 8                   0.09
   Creatinine, μmol/l                       65 (52--88)            77 (57--128)         122 (74--264)             \<0.01
   Total bilirubin, μmol/l                  17 (10--29)            15 (10--24)          18 (11--37)               0.10
  Variables collected at beginning of NIV                                                                         
   GCS                                      14.6 ± 1.6             14.6 ± 1.2           14.4 ± 1.1                0.49
   Heart rate, beats/min                    113 ± 21               114 ± 23             125 ± 21                  \<0.01
   Respiratory rate, breaths/min            31 ± 8                 32 ± 7               33 ± 8                    0.44
   Mean arterial pressure, mmHg             99 ± 18                96 ± 16              80 ± 16                   \<0.01
   pH                                       7.42 ± 0.09            7.43 ± 0.08          7.39 ± 0.11               \<0.01
   PaCO~2~, mmHg                            36 ± 7                 34 ± 7               32 ± 9                    \<0.01
   PaO~2~/FiO~2~, mmHg                      172 ± 71               146 ± 50             165 ± 66                  \<0.01

APACHE II, acute physiology and chronic health evaluation II; GCS, Glasgow coma scale; NIV, noninvasive ventilation; SOFA, sequential organ failure assessment.

Comparison between three groups.

###### 

Univariate and multivariate analysis for NIV failure.

![](10.1177_1753466619888124-table2)

                                            Univariate analysis OR (95% CI)   *p*      Multivariate analysis OR (95% CI)   *p*
  ----------------------------------------- --------------------------------- -------- ----------------------------------- --------
  Age, years                                1.008 (0.998--1.018)              0.14     1.014 (1.002--1.025)                0.02
  Infection condition                                                                                                      
   Sepsis (*versus* nonsepsis)              2.10 (1.17--3.75)                 \<0.01   1.95 (1.06--3.61)                   0.03
   Septic shock (*versus* nonsepsis)        5.28 (2.61--10.69)                \<0.01   2.47 (1.12--5.45)                   0.03
  Solid tumor                               1.23 (0.76--2.00)                 0.40     --                                  --
  Chronic heart disease                     1.06 (0.68--1.65)                 0.80     --                                  --
  Chronic respiratory disease               0.92 (0.56--1.52)                 0.75     --                                  --
  Presence of immunosuppression             1.77 (1.04--3.01)                 0.04     --                                  --
  APACHE II score                           1.09 (1.06--1.13)                 \<0.01   --                                  --
  SOFA score                                1.24 (1.16--1.34)                 \<0.01   1.22 (1.12--1.32)                   \<0.01
  Platelet counts                           0.999 (0.997--1.000)              0.07     --                                  --
  Albumin, g/l                              0.96 (0.93--0.99)                 \<0.01   0.96 (0.93--1.00)                   0.03
  Variables collected at beginning of NIV                                                                                  
   Respiratory rate, breaths/min            1.07 (1.04--1.10)                 \<0.01   1.07 (1.04--1.10)                   \<0.01
   Heart rate, beats/min                    1.01 (1.00--1.02)                 0.04     --                                  --
   Mean arterial pressure, mmHg             0.988 (0.978--0.999)              0.03     --                                  --
   GCS                                      0.92 (0.80--1.05)                 0.22     --                                  --
   pH                                       0.23 (0.03--1.61)                 0.14     --                                  --
   PaCO~2~, mmHg                            0.97 (0.94--0.99)                 \<0.01   --                                  --
   PaO~2~/FiO~2~, mmHg                      0.997 (0.994--1.000)              0.06     --                                  --

APACHE II, acute physiology and chronic health evaluation II; CI, confidence internal; GCS, Glasgow coma scale; NIV, noninvasive ventilation; OR, odds ratio; SOFA, sequential organ failure assessment.

NIV failure increased from 23% to 38% from no-sepsis to sepsis patients, and it increased further to 61% in septic shock patients ([Table 3](#table3-1753466619888124){ref-type="table"}). ICU and hospital mortality also increased from no-sepsis to septic shock patients. Sequential organ failure assessment (SOFA) score was independently associated with NIV failure (OR = 1.22, 95% CI: 1.12--1.32). Among the patients with sepsis and septic shock, NIV failure increased with increase in SOFA scores ([Figure 1](#fig1-1753466619888124){ref-type="fig"}).

###### 

Outcomes.

![](10.1177_1753466619888124-table3)

                       No sepsis (*n* = 75)   Sepsis (*n* = 365)   Septic shock (*n* = 79)   *p* ^[a](#table-fn5-1753466619888124){ref-type="table-fn"}^
  -------------------- ---------------------- -------------------- ------------------------- -------------------------------------------------------------
  NIV failure          17 (23%)               139 (38%)            48 (61%)                  \<0.01
  ICU stay             6.4 (4.0--9.0)         7.2 (4.2--13.2)      6.8 (3.4--12.8)           0.09
  Hospital stay        15.8 (8.9--21.8)       16.0 (8.1--25.5)     16.0 (8.3--29.0)          0.84
  ICU mortality        7 (9%)                 64 (18%)             19 (24%)                  0.05
  Hospital mortality   9 (12%)                79 (22%)             21 (27%)                  0.07

ICU, intensive care unit; NIV, noninvasive ventilation.

Comparison between three groups.

![NIV failure rate in patients with sepsis and septic shock on different SOFA scores.\
NIV, noninvasive ventilation; SOFA, sequential organ failure assessment.](10.1177_1753466619888124-fig1){#fig1-1753466619888124}

[Table 4](#table4-1753466619888124){ref-type="table"} shows the characteristics of the patients whose infection came from pulmonary and nonpulmonary sources. Septic shock patients were more common in nonpulmonary infection (37% *versus* 10%, *p* \< 0.01). They also had higher SOFA scores, higher creatinine, higher total bilirubin, and higher heart rate. The NIV failure rate was similar between pulmonary and nonpulmonary infection (43% *versus* 40%, *p* = 0.59). However, patients with nonpulmonary infection had lower ICU and hospital mortality than those with pulmonary infection (10% *versus* 22%, *p* \< 0.01, and 14% *versus* 26%, *p* \< 0.01, respectively).

###### 

Comparisons between sepsis and septic shock patients with different infection origins.

![](10.1177_1753466619888124-table4)

                                            Pulmonary origin (*n* = 319)   Nonpulmonary origin (*n* = 125)   *p*
  ----------------------------------------- ------------------------------ --------------------------------- --------
  Age, years                                63 ± 18                        60 ± 17                           0.10
  Male (%)                                  223 (70%)                      77 (62%)                          0.11
  APACHE II score                           16 ± 5                         16 ± 4                            0.55
  SOFA score                                5.1 ± 2.5                      6.6 ± 3.2                         \<0.01
  Presence of immunosuppression             53 (17%)                       4 (3%)                            \<0.01
  Presence of sepsis                        286 (90%)                      79 (63%)                          \<0.01
  Presence of septic shock                  33 (10%)                       46 (37%)                          \<0.01
  Comorbidity                                                                                                
   Hypertension                             123 (39%)                      45 (36%)                          0.66
   Diabetes mellitus                        65 (20%)                       38 (30%)                          0.03
   Solid tumor                              38 (12%)                       22 (18%)                          0.12
   Chronic heart disease                    64 (20%)                       23 (18%)                          0.79
   Chronic respiratory disease              57 (18%)                       7 (6%)                            \<0.01
  Laboratory tests                                                                                           
   White blood cell counts, ×10^9^/l        12 ± 8                         15 ± 10                           \<0.01
   Platelet counts, ×10^9^/l                193 ± 109                      187 ± 135                         0.61
   Hemoglobin, mg/dl                        11.0 ± 2.8                     10.4 ± 3.0                        0.06
   Albumin, g/l                             30 ± 6                         29 ± 6                            0.10
   Potassium, mmol/l                        4.0 ± 0.7                      4.1 ± 0.8                         0.36
   Sodium, mmol/l                           137 ± 7                        140 ± 7                           \<0.01
   Chlorine, mmol/l                         102 ± 7                        105 ± 7                           \<0.01
   Creatinine, μmol/l                       77 (57--127)                   110 (70--191)                     \<0.01
   Total bilirubin, μmol/l                  15 (10--23)                    19 (12--40)                       \<0.01
  Variables collected at beginning of NIV                                                                    
   GCS                                      14.6 ± 1.4                     14.6 ± 0.8                        0.86
   Heart rate, beats/min                    113 ± 23                       123 ± 21                          \<0.01
   Respiratory rate, breaths/min            32 ± 7                         32 ± 7                            0.69
   Mean arterial pressure, mmHg             94 ± 17                        90 ± 17                           \<0.01
   pH                                       7.43 ± 0.08                    7.40 ± 0.10                       \<0.01
   PaCO~2~, mmHg                            34 ± 7                         32 ± 8                            0.04
   PaO~2~/FiO~2~, mmHg                      141 ± 49                       171 ± 60                          \<0.01
  NIV failure                               137 (43%)                      50 (40%)                          0.59
  ICU stay                                  7.1 (4.2--13.1)                7.1 (3.9--13.7)                   0.89
  Hospital stay                             15.0 (7.8--24.7)               18.8 (9.8--36.3)                  \<0.01
  ICU mortality                             71 (22%)                       12 (10%)                          \<0.01
  Hospital mortality                        83 (26%)                       17 (14%)                          \<0.01

APACHE II, acute physiology and chronic health evaluation II; GCS, Glasgow coma scale; NIV, noninvasive ventilation; SOFA, sequential organ failure assessment.

Discussion {#section9-1753466619888124}
==========

Current study explored the association between NIV failure and the severity of sepsis. We found that sepsis was independently associated with NIV failure in patients with hypoxemic respiratory failure, and the association was stronger in septic shock patients. The organ dysfunction caused by sepsis were positively correlated with NIV failure.

The use of NIV in hypoxemic respiratory failure is controversial.^[@bibr21-1753466619888124]^ Delayed intubation due to improper use of NIV increases hospital mortality.^[@bibr12-1753466619888124],[@bibr22-1753466619888124]^ Our study found that patients with sepsis were more likely to experience NIV failure, and much more likely if they had septic shock. So, NIV should be used cautiously in such patients. Furthermore, Serpa and colleagues have suggested that NIV should be used in selected cases of mild respiratory failure with preserved or relatively stable hemodynamic status, and that frequent reassessments of therapeutic effect are required in order to prevent delay in intubation.^[@bibr23-1753466619888124]^

The overall NIV failure rate in our study was 39%. This rate was at the median value reported previously.^[@bibr4-1753466619888124][@bibr5-1753466619888124][@bibr6-1753466619888124]--[@bibr7-1753466619888124]^ However, in patients with no-sepsis, the NIV failure rate was 23%, much lower than the median value. In this group, oxygenation was highest and APACHE II and SOFA scores were lowest. So finding the lowest NIV failure rate in this group is not surprising. On the contrary, the NIV failure rate in patients with septic shock was 61%, the highest among the three groups in our study. Patients in this group had higher APACHE II scores, higher SOFA scores, and higher heart rate. Previous studies have demonstrated that patients with high APACHE II score, SOFA score, and heart rate were more likely to experience NIV failure.^[@bibr6-1753466619888124],[@bibr8-1753466619888124],[@bibr24-1753466619888124]^ Therefore, these reasons explain the high NIV failure rate in patients with septic shock.

Sepsis is common in ICUs. A recent multi-center observational study reported an incidence of 30.2 per 100 ICU beds in Brazilian ICUs.^[@bibr25-1753466619888124]^ Previous studies have reported that sepsis is associated with NIV failure.^[@bibr4-1753466619888124],[@bibr15-1753466619888124]^ Although these studies provided important knowledge in this field, they failed to stratify the severity of sepsis. In the current study, we stratified sepsis and reported associations between NIV failure and sepsis severity. As use of NIV in patients with hypoxemic respiratory failure is controversial, our data provide some references for use of NIV in this population.

Sepsis results mostly from pulmonary infection.^[@bibr13-1753466619888124],[@bibr26-1753466619888124]^ Our study confirmed this. However, unlike previous studies, we found the interesting result that patients with sepsis from pulmonary infection had a similar NIV failure rate but higher mortality than those whose sepsis came from nonpulmonary infection, although nonpulmonary infection patients had a higher proportion of septic shock, higher SOFA score, and higher heart rate. Previous studies have reported that pulmonary-infection-induced sepsis resulted in higher mortality than nonpulmonary infection.^[@bibr27-1753466619888124][@bibr28-1753466619888124]--[@bibr29-1753466619888124]^ And pulmonary-infection-induced sepsis became an independent risk factor for 28-day in-hospital mortality.^[@bibr29-1753466619888124]^ The reasons were unclear, but may possibly have been due to ARDS. In our study, the PaO~2~/FiO~2~ in the pulmonary infection group was much lower than in the nonpulmonary infection group, meaning that pulmonary infection leads to greater severity of lung injury. This may explain the higher mortality in the pulmonary infection group.

This study has several limitations. We excluded patients with hypercapnic respiratory failure because these patients receive much benefit from NIV.^[@bibr30-1753466619888124]^ This may bias the incidence of sepsis and septic shock in the NIV population. In addition, this is a multi-center observational study performed in 16 Chinese ICUs. We applied recommended criteria for intubation. However, the decision to intubate was at the attending physicians' discretion. This may bias NIV failure rate. On the efficacy of NIV, we found only that NIV failure was associated with sepsis and septic shock. Whether patients with sepsis syndrome benefit from NIV requires to be confirmed by randomized control trials.

In conclusion, sepsis was associated with NIV failure in patients with hypoxemic respiratory failure, and the association was stronger in septic shock patients. NIV failure increased with the increase of organ dysfunction caused by sepsis. Patients with sepsis induced by pulmonary infection were more likely to die in hospital.
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